



The Cannabinoids Opportunity

Radient's MAPTM Extraction Technology establishes new standards in the cannabinoids industry

Radient's proprietary Microwave Assisted Processing MAP^{TM} technology has applications across a wide range of verticals, including nutritional supplements, food, cosmetics, oil & gas, tobacco and now - of increasing relevance - the fast growing cannabinoids market.

Over the past decade, Radient has consistently demonstrated the ability to increase the yield and the concentration of the active ingredients from plants in a very cost-efficient manner.

Most recently, favourable changes have occurred in the cannabis legislation, both for marijuana and hemp, allowing for a fast-paced growth of the industry. Although both marijuana and hemp both contain cannabinoids, they differ in their specific concentration of the psychoactive and non-psychoactive forms. These include certain molecules with proven medical benefits including Cannabadiol (CBD) and a related molecule called Tetrahydrocannabinol (THC), responsible for cannabis' psychoactive properties. Current research has revealed over 60 different additional cannabinoids, although THC is the most well known. THC is credited with causing the marijuana high. Regulators typically limit the concentration of THC in cannabis.

The Radient Advantage

Radient is currently taking advantage of its superior extraction technology to establish itself as a leading North American player, capturing value in both the marijuana and hemp markets. Compared to conventional extraction technologies, Radient is capable of extracting cannabinoids with a higher efficiency, and to develop standardized extracts with specific concentrations of cannabinoids. of interest to the therapeutic industry. Further, Radient's full-scale, GMP certified extraction facility will allow the Company to easily capitalize on the industry's desire to partner with a reputable extraction expert able to offer product manufacturing under strict Quality Assurance and Quality Control while possessing the necessary capacity to meet demand.

The Cannabinoids industry requires various standardized extracts at high purity level and derived from specific strains that can be smoked, vaporized, ingested, or topically applied. This is where Radient comes into play.

Because of the favorable regulation in Canada and its unique positioning, Radient has applied to become a commercial licensed producer of medical cannabis oil pursuant to Health Canada's *Access to Cannabis for Medical Purposes Regulations* ("ACMPR").



Radient is interested in partnering with researchers, growers and companies having complementary skills to establish itself as a North America leader in the development of standardized cannabinoid extracts from both marijuana and hemp.

On December14, 2016, Radient jointly announced with Aurora Cannabis Inc. that they have signed a memorandum of understanding to evaluate an exclusive partnership for the Canadian market with regard to the joint development and commercialization of superior and standardized marijuana extracts. Aurora is one of the largest licensed producers of medical cannabis under Health Canada's ACMPR.

Radient is advancing discussions with other groups where similar synergies could be achieved in markets outside of Canada.